2. Search Result
Search Result
Results for "

Enpp1+Inhibitors

" in MedChemExpress (MCE) Product Catalog:
Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-176708
    ISM5939

    		Phosphodiesterase (PDE) Cancer
    ISM5939 is an orally active and selective ENPP1 inhibitor with an IC50 of 0.63 nM for 2,3-cGAMP degradation and 9.28 nM for ATP hydrolysis. ISM5939 has antitumor activity [1].
    ISM5939
  • HY-147389
    Enpp-1-IN-14
    1 Publications Verification

    		 Phosphodiesterase (PDE) Cancer
    Enpp-1-IN-14 (Compound 015) is a potent Ectonucleotide Pyrophosphatase/Phosphodiesterase-1 (ENPP1) inhibitor with an IC50 value of 32.38 nM for recombinant human ENPP-1. Enpp-1-IN-14 has anti-tumor activity [1].
    Enpp-1-IN-14
  • HY-143256
    Enpp-1-IN-12

    		Phosphodiesterase (PDE) Cancer
    Enpp-1-IN-12 (compound 43) is a potent and orally active ecto-nucleotide pyrophosphatase/phosphodiesterases 1 (ENPP1) inhibitor, with a Ki of 41 nM. Enpp-1-IN-12 exhibits anti-tumor activity [1].
    Enpp-1-IN-12
  • HY-163343
    Enpp-1-IN-20

    		Phosphodiesterase (PDE) STING Cancer
    Enpp-1-IN-20 (Compound 31) is an ectonucleotide pyrophosphatase/phosphodiesterase 1 (ENPP1) inhibitor, with an IC50 of 0.09 nM. Enpp-1-IN-20 has strongest inhibitory activity in the cell-based assay, with an IC50 of 8.8 nM. Enpp-1-IN-20 has significant potency in both ENPP1 inhibition and STING pathway stimulation in vitro. Enpp-1-IN-20 can be used for the research of cancer [1].
    Enpp-1-IN-20
  • HY-155457
    Enpp-1-IN-19

    		Phosphodiesterase (PDE) STING Cancer
    Enpp-1-IN-19 (compound 29f) is an orally active ENPP1 inhibitor that inhibits cGAMP hydrolysis by ENPP1 (IC50=68 nM). Enpp-1-IN-19 increases anti-PD-L1 responses and inhibits tumor growth in CT26 syngeneic models. Enpp-1-IN-19 also enhances STING-mediated type I interferon responses, induces immune memory, and prevents tumor recurrence [1].
    Enpp-1-IN-19
  • HY-143254
    Enpp-1-IN-10

    		Phosphodiesterase (PDE) Cancer
    Enpp-1-IN-10 (compound 1) is a potent Ecto-nucleotide pyrophosphatase/phosphodiesterases 1 (ENPP1) inhibitor with an Ki value of 3.866 μM. Enpp-1-IN-10 can be used for researching anticancer [1].
    Enpp-1-IN-10
  • HY-176296
    Vizenpistat

    SR-8541A

    		 Phosphodiesterase (PDE) STING Cancer
    Vizenpistat is an orally active ENPP1 inhibitor. Vizenpistat increases cGAMP levels, blocks 2′3′-cGAMP hydrolysis, inhibits adenosine production, regulates innate immune signaling mediated by the STING pathway, and modulates anti-tumor immune responses. Vizenpistat is applicable to research related to breast cancer and metastatic microsatellite-stable colorectal cancer [1] .
    Vizenpistat
  • HY-143255
    Enpp-1-IN-11

    		Phosphodiesterase (PDE) Cancer
    Enpp-1-IN-11 (compound 23) is a potent Ecto-nucleotide pyrophosphatase/phosphodiesterases 1 (ENPP1) inhibitor with an Ki value of 45 nM. Enpp-1-IN-11 exhibits low clearance in human and mouse liver microsomes, good plasma stability in human and mouse plasma. Enpp-1-IN-11 can be used for researching anticancer [1].
    Enpp-1-IN-11
  • HY-153335
    Enpp-1-IN-16

    		Phosphodiesterase (PDE) Infection Cardiovascular Disease Metabolic Disease Inflammation/Immunology Cancer
    Enpp-1-IN-16 (compound 54) is an ENPP1 inhibitor. Enpp-1-IN-16 has the potential to study cancer, especially in cases of high ENPP1 expression or elevated cytoplasmic DNA levels. Enpp-1-IN-16 can also be used in other diseases mediated by ENPP1, such as bacterial or viral infections, insulin resistance and type II diabetes, chondrocalcinosis and osteoarthritis, calcium pyrophosphate deposition disorder (CPPD), low Phosphatase disease and soft tissue calcification disorders [1].
    Enpp-1-IN-16
  • HY-175478
    Enpp-1-IN-27

    		Phosphodiesterase (PDE) STING Inflammation/Immunology Cancer
    Enpp-1-IN-27 is a selective ENPP1 inhibitor with an IC50 of 14.68 nM, exhibiting approximately 410-fold selectivity against ENPP2 and 10-fold selectivity against ENPP3. Enpp-1-IN-27 stabilizes cGAMP levels and activates the STING pathway, promoting cytokine release and enhancing innate immune responses. Enpp-1-IN-27 induces ISRE activation and amplified cGAMP-mediated immune responses and shows the desired antitumor efficacy in the 4T1 and CT26 syngeneic mouse models. Enpp-1-IN-27 can used for the studies of breast cancer and colon cancer [1].
    Enpp-1-IN-27
  • HY-153334
    Enpp-1-IN-15

    		Phosphodiesterase (PDE) Others
    Enpp-1-IN-15 (Compound 88a) is an Ectonucleotide Pyrophosphatase/Phosphodiesterase 1 (Enpp-1) Inhibitor, with a Ki value of 0.00586 nM [1].
    Enpp-1-IN-15
  • HY-176828
    Enpp-1-IN-28

    		Phosphodiesterase (PDE) Cancer
    Enpp-1-IN-28 is a ENPP1 inhibitor at the molecular and cellular levels, with IC50 values of 0.188 µM and 0.732 µM, respectively. Enpp-1-IN-28 upgrades the expression levels of IFN-β in vivo by preventing the ENPP1 from hydrolyzing the cGAMP to stimulate a more potent innate immune response. Enpp-1-IN-28 can be used for the study of metastatic breast cancer [1].
    Enpp-1-IN-28
  • HY-176874
    Enpp-1-IN-29

    		Phosphodiesterase (PDE) Inflammation/Immunology Cancer
    Enpp-1-IN-29 (Compound 1) is a highly selective ectonucleotide pyrophosphatase/phosphodiesterase 1 (ENPP1) inhibitor (IC50=0.05 nM). Enpp-1-IN-29 is promising for research of ENPP1-overexpressing cancers (e.g., breast cancer, head/neck cancer, metastatic chromosome-unstable tumors) and immune-related diseases (e.g., autoimmune disorders, tumor immune evasion) [1].
    Enpp-1-IN-29
  • HY-162911
    Enpp-1-IN-22

    		Phosphodiesterase (PDE) Cancer
    Enpp-1-IN-22 is an orally bioavailable prodrug of the potent ENPP1 inhibitor paraformaldehyde with antitumor activity [1].
    Enpp-1-IN-22
  • HY-157522
    NCI-14465

    		Phosphodiesterase (PDE) Cancer
    NCI-14465 is an ectonucleotide pyrophosphatase/phosphodiesterase (ENPP1) inhibitor with an IC 50 of 26.4 μM. NCI-14465 can be used in cancer research [1].
    NCI-14465
  • HY-162912
    Enpp-1-IN-23

    		Phosphodiesterase (PDE) Cancer
    Enpp-1-IN-23 (compound 27) is an Enpp-1 inhibitor, with IC50 of 1.2 nM. Enpp-1-IN-23 can be used in cancer research [1].
    Enpp-1-IN-23
  • HY-168147
    Enpp-1-IN-24

    		Phosphodiesterase (PDE) Cancer
    Enpp-1-IN-24 (compund 7) is an ENPP1 inhibitor that, in combination with anti-PD-1 antibodies, achieves 77.7% tumor growth inhibition and improves survival in mouse models [1].
    Enpp-1-IN-24
  • HY-153398
    Enpp-1-IN-17

    		Phosphodiesterase (PDE) Infection Cancer
    Enpp-1-IN-17 (example 274) is a potent ENPP1 inhibitor, with the inhibition constants (Ki values) toward cGAMP and ATP hydrolysis of 100 nM-1 μM and > 1 μM, respectively. The selectivity ratio for inhibition of cGAMP hydrolysis versus ATP hydrolysis is >6.4 [1].
    Enpp-1-IN-17
  • HY-175047
    Enpp-1-IN-26

    		Phosphodiesterase (PDE) Cancer
    Enpp-1-IN-26 (Compound 4e) is an ENPP1 inhibitor with an IC50 of 0.188 μM. Enpp-1-IN-26 enhances IFN-β expression in vivo by preventing ENPP1 from hydrolyzing cGAMP. Enpp-1-IN-26 can be used in the research of metastatic breast cancer [1].
    Enpp-1-IN-26
  • HY-168491
    Enpp-1-IN-25

    		Phosphodiesterase (PDE) STING PD-1/PD-L1 Cancer
    Enpp-1-IN-25 (Compound 30) is an ENPP1 inhibitor with an IC50 of 8.05 nM and low oral bioavailability. Enpp-1-IN-25 can effectively activate the intracellular STING pathway by inhibiting cGAMP degradation. Enpp-1-IN-25 can enhance immune cell infiltration in the tumor microenvironment and type I interferon responses, and potentiate the antitumor efficacy of the anti-PD-L1 antibody. Enpp-1-IN-25 can be used in the research of cancer immunotherapy [1].
    Enpp-1-IN-25
  • HY-149465
    STF-1623

    		Phosphodiesterase (PDE) STING Neurological Disease Cancer
    STF-1623 is a highly potent ENPP1 inhibitor with an IC50 of 0.6 nM. STF-1623 inhibits ENPP1, activates tumor-specific STING signaling. STF-1623 blocks breast, pancreatic, colon, and brain cancer progression [1].
    STF-1623
  • HY-182772
    Enpp-1-IN-31

    		Phosphodiesterase (PDE) Cancer
    Enpp-1-IN-31 is a ENPP1 inhibitor with an IC50 of <20 nM (using cGAMP as the substrate). Enpp-1-IN-31 exhibits potential anticancer activity and inhibits the growth and proliferation of mouse colon cancer cells and breast cancer cells [1].
    Enpp-1-IN-31
  • HY-181667
    Enpp-1-IN-30

    		Phosphodiesterase (PDE) Cancer
    Enpp-1-IN-30 (compound 44a) is an orally bioavailable ENPP1 inhibitor with a human IC50 of 13.1 nM. Enpp-1-IN-30 prevents cGAMP degradation, activates the STING pathway. Enpp-1-IN-30 induces cytokine release to enhance innate immune response. Enpp-1-IN-30 exerts antitumor efficacy in syngeneic mouse models. Enpp-1-IN-30 can be used for the research of colon carcinoma [1].
    Enpp-1-IN-30

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: